BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

Impending LOEs for key drugs ( ~$17B peak revenue by 2026-2030) are a concern, but Pfizer is actively investing in its pipeline, especially oncology and vaccines, to offset this. Pfizer's robust ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...